Allarity Therapeutics will present a Trial-in-Progress poster on its ongoing Phase 2 stenoparib trial at the ESMO Gynaecological Cancers Congress 2026 in Copenhagen. The poster, presented by Principal Investigator Kathleen N. Moore, outlines the study design and clinical rationale for evaluating stenoparib in patients with advanced platinum-resistant or platinum-ineligible ovarian cancer, building on prior Phase 2 clinical experience that showed durable clinical benefit in heavily pretreated patients. As a Trial-in-Progress presentation, it does not include new clinical data. The poster will be available on the company's website following its presentation on June 18, 2026.
Allarity Therapeutics IncTrial-in-progress poster presentation at a medical congress, but no new clinical data disclosed.